J Gynecol Oncol.  2015 Oct;26(4):249-251. 10.3802/jgo.2015.26.4.249.

Uterine carcinosarcoma/malignant mixed Mullerian tumor incidence is increased in women with breast cancer, but independent of hormone therapy

• Wilson BT
• Cordell HJ

• KMID: 2345913
• DOI: http://doi.org/10.3802/jgo.2015.26.4.249

Abstract

No abstract available.

MeSH Terms

Adult
Aged
Aged, 80 and over
Breast Neoplasms/*epidemiology/genetics
Carcinosarcoma/*epidemiology/genetics
Cohort Studies
England/epidemiology
Female
Genes, BRCA1
Genes, BRCA2
Hormone Replacement Therapy/*statistics & numerical data
Humans
Incidence
Kaplan-Meier Estimate
Middle Aged
Mixed Tumor, Mullerian/*epidemiology/genetics
Mutation/genetics
Neoplasms, Second Primary/*epidemiology
Uterine Neoplasms/*epidemiology/genetics

Figure

• 

  Fig. 1 Kaplan-Meier estimates of time to uterine carcinosarcoma/malignant mixed Müllerian tumor (UC/MMMT) following breast cancer diagnosis, with and without hormone therapy for the breast cancer. There is no difference between the groups.

Reference

1. Kernochan LE, Garcia RL. Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw. 2009; 7:550–556.

2. Ho SP, Ho TH. Malignant mixed Mullerian tumours of the uterus: a ten-year experience. Singapore Med J. 2002; 43:452–456.

3. Friedrich M, Villena-Heinsen C, Mink D, Bonkhoff H, Schmidt W. Carcinosarcoma, endometrial intraepithelial carcinoma and endometriosis after tamoxifen therapy in breast cancer. Eur J Obstet Gynecol Reprod Biol. 1999; 82:85–87.

4. Fotiou S, Hatjieleftheriou G, Kyrousis G, Kokka F, Apostolikas N. Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: two case-reports and review of the literature. Anticancer Res. 2000; 20:2015–2020.

5. McCluggage WG, Abdulkader M, Price JH, Kelehan P, Hamilton S, Beattie J, et al. Uterine carcinosarcomas in patients receiving tamoxifen: a report of 19 cases. Int J Gynecol Cancer. 2000; 10:280–284.

6. Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, et al. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer. 2002; 12:496–500.

7. Hubalek M, Ramoni A, Mueller-Holzner E, Marth C. Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer. Gynecol Oncol. 2004; 95:264–266.

8. Yildirim Y, Inal MM, Sanci M, Yildirim YK, Mit T, Polat M, et al. Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases. Int J Gynecol Cancer. 2005; 15:1239–1242.

9. Arenas M, Rovirosa A, Hernandez V, Ordi J, Jorcano S, Mellado B, et al. Uterine sarcomas in breast cancer patients treated with tamoxifen. Int J Gynecol Cancer. 2006; 16:861–865.

10. Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst. 2004; 96:70–74.

11. Rieck GC, Freites ON, Williams S. Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer. J Obstet Gynaecol. 2005; 25:39–41.

12. Swerdlow AJ, Jones ME. British Tamoxifen Second Cancer Study Group. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst. 2005; 97:375–384.

13. Saadat M, Truong PT, Kader HA, Speers CH, Berthelet E, McMurtrie E, et al. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen. Cancer. 2007; 110:31–37.

14. Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, et al. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta. Biochem Biophys Res Commun. 1997; 236:140–145.

15. Zafrakas M, Kostopoulou E, Dragoumis K, Mikos T, Papadimas J, Bontis J. Expression of estrogen receptors alpha and beta in two uterine mesenchymal tumors after prolonged tamoxifen therapy: report of two cases. Eur J Gynaecol Oncol. 2004; 25:530–533.

16. Raspollini MR, Mecacci F, Paglierani M, Marchionni M, Taddei GL. HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. Pathol Res Pract. 2005; 201:141–144.

17. Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L, Moerman P, et al. ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecol Oncol. 2004; 95:583–587.

18. Marques MM, Beland FA. Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide. Carcinogenesis. 1997; 18:1949–1954.

19. Martin EA, Brown K, Gaskell M, Al-Azzawi F, Garner RC, Boocock DJ, et al. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res. 2003; 63:8461–8465.

20. Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol. 2013; 130:127–131.

21. Pennington KP, Walsh T, Lee M, Pennil C, Novetsky AP, Agnew KJ, et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer. 2013; 119:332–338.

22. Hecht JL, Konstantinopoulos PA, Awtrey CS, Soslow RA. Immunohistochemical loss of BRCA1 protein in uterine serous carcinoma. Int J Gynecol Pathol. 2014; 33:282–287.

23. Evans DG, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2013; 140:135–142.

24. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011; 103:334–346.